Analysts Set Krystal Biotech, Inc. (NASDAQ:KRYS) Target Price at $177.63

Krystal Biotech, Inc. (NASDAQ:KRYS) has been assigned an average recommendation of “Buy” from the nine analysts that are presently covering the company, Marketbeat.com reports. Nine research analysts have rated the stock with a buy rating. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $177.63.

A number of equities analysts have commented on the stock. Stifel Nicolaus reiterated a “buy” rating and issued a $204.00 price objective (up previously from $178.00) on shares of Krystal Biotech in a report on Tuesday, April 16th. HC Wainwright reiterated a “buy” rating and issued a $200.00 price objective on shares of Krystal Biotech in a report on Monday, May 6th. Citigroup boosted their price objective on shares of Krystal Biotech from $160.00 to $195.00 and gave the stock a “buy” rating in a report on Tuesday, February 27th. Guggenheim boosted their price objective on shares of Krystal Biotech from $130.00 to $175.00 and gave the stock a “buy” rating in a report on Tuesday, February 27th. Finally, William Blair reiterated an “outperform” rating on shares of Krystal Biotech in a report on Tuesday, February 27th.

Insider Activity

In other news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction that occurred on Tuesday, June 11th. The shares were sold at an average price of $175.76, for a total value of $4,394,000.00. Following the completion of the transaction, the insider now directly owns 1,525,882 shares in the company, valued at $268,189,020.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction that occurred on Tuesday, June 11th. The shares were sold at an average price of $175.76, for a total transaction of $4,394,000.00. Following the completion of the sale, the insider now directly owns 1,525,882 shares in the company, valued at $268,189,020.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Julian S. Gangolli sold 20,000 shares of the firm’s stock in a transaction that occurred on Monday, May 20th. The stock was sold at an average price of $164.13, for a total transaction of $3,282,600.00. The disclosure for this sale can be found here. Insiders own 14.10% of the company’s stock.

Institutional Trading of Krystal Biotech

A number of large investors have recently added to or reduced their stakes in the business. Quest Partners LLC purchased a new stake in shares of Krystal Biotech in the 4th quarter valued at approximately $127,000. Pier 88 Investment Partners LLC purchased a new stake in Krystal Biotech in the 4th quarter worth approximately $145,000. Caxton Associates LP purchased a new stake in Krystal Biotech in the 1st quarter worth approximately $232,000. Lazard Asset Management LLC lifted its position in Krystal Biotech by 27.5% in the 1st quarter. Lazard Asset Management LLC now owns 1,308 shares of the company’s stock worth $232,000 after buying an additional 282 shares in the last quarter. Finally, Headlands Technologies LLC purchased a new stake in Krystal Biotech in the 1st quarter worth approximately $291,000. 86.29% of the stock is currently owned by institutional investors.

Krystal Biotech Stock Performance

Shares of KRYS opened at $177.71 on Friday. The stock has a fifty day moving average of $164.87 and a two-hundred day moving average of $146.06. The company has a market capitalization of $5.08 billion, a PE ratio of 95.03 and a beta of 0.90. Krystal Biotech has a fifty-two week low of $93.95 and a fifty-two week high of $191.78.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings data on Monday, May 6th. The company reported $0.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.20 by ($0.17). The firm had revenue of $45.25 million for the quarter, compared to the consensus estimate of $47.37 million. During the same period in the previous year, the company earned ($1.76) earnings per share. The firm’s revenue for the quarter was up 452400.0% on a year-over-year basis. As a group, equities research analysts forecast that Krystal Biotech will post 2.06 earnings per share for the current fiscal year.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).